In:
Blood, American Society of Hematology, Vol. 130, No. 18 ( 2017-11-02), p. 1985-1994
Kurzfassung:
WT1-specific TCR-redirected T-cell therapy for AML and MDS is safe, and the T cells persisted in vivo and trafficked to bone marrow. Transient decreases of leukemic cell in bone marrow were shown.
Materialart:
Online-Ressource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood-2017-06-791202
Sprache:
Englisch
Verlag:
American Society of Hematology
Publikationsdatum:
2017
ZDB Id:
1468538-3
ZDB Id:
80069-7